APD-209 / Adenovir - LARVOL DELTA

Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC) (clinicaltrials.gov) - P2; N=47; Completed; Sponsor: Adenovir Pharma AB; Recruiting ➔ Completed; N=130 ➔ 47; Trial primary completion date: Dec 2016 ➔ Sep 2016

Enrollment change • Trial completion • Trial primary completion date • Biosimilar • Dry Eye Disease • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology